Benefits of candesartan are consistent regardless of pre-treatment systolic blood pressure in the candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) program.
Publication
, Conference
Meredith, PA; Ostergren, J; McMurray, JJV; Granger, CB; Swedberg, K; Yusuf, S; Michelson, EL; Olofsson, B; Puu, M; Solomon, SD; Pfeffer, MA
Published in: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
2007
Duke Scholars
Published In
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
ISSN
0735-1097
Publication Date
2007
Volume
49
Issue
9
Start / End Page
331A / 331A
Related Subject Headings
- Cardiovascular System & Hematology
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Meredith, P. A., Ostergren, J., McMurray, J. J. V., Granger, C. B., Swedberg, K., Yusuf, S., … Pfeffer, M. A. (2007). Benefits of candesartan are consistent regardless of pre-treatment systolic blood pressure in the candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) program. In JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (Vol. 49, pp. 331A-331A).
Meredith, P. A., J. Ostergren, J. J. V. McMurray, C. B. Granger, K. Swedberg, S. Yusuf, E. L. Michelson, et al. “Benefits of candesartan are consistent regardless of pre-treatment systolic blood pressure in the candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) program.” In JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 49:331A-331A, 2007.
Meredith PA, Ostergren J, McMurray JJV, Granger CB, Swedberg K, Yusuf S, et al. Benefits of candesartan are consistent regardless of pre-treatment systolic blood pressure in the candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) program. In: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2007. p. 331A-331A.
Meredith, P. A., et al. “Benefits of candesartan are consistent regardless of pre-treatment systolic blood pressure in the candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) program.” JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 49, no. 9, 2007, pp. 331A-331A.
Meredith PA, Ostergren J, McMurray JJV, Granger CB, Swedberg K, Yusuf S, Michelson EL, Olofsson B, Puu M, Solomon SD, Pfeffer MA. Benefits of candesartan are consistent regardless of pre-treatment systolic blood pressure in the candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) program. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2007. p. 331A-331A.
Published In
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
ISSN
0735-1097
Publication Date
2007
Volume
49
Issue
9
Start / End Page
331A / 331A
Related Subject Headings
- Cardiovascular System & Hematology
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1102 Cardiorespiratory Medicine and Haematology